Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Every year, a new list of players is inducted, and this time, there are 15 finalists left, including former New York Giants quarterback Eli Manning, who is attempting to make it in his first year ...

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

Eli Lilly also states that vial forms are cheaper than the auto-injector pre-filled pens ... There is also an FDA box warning for thyroid C-cell tumors for this medication. The prescribing ...

Considering that GLP-1 drugs currently require a regular injection, it's likely many patients will opt for a straightforward pill option instead if given the choice. Besides that, Eli Lilly has ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $725.72. According to ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE ... joined ‘Squawk Box’ on CNBC to discuss that the long-term market trends look positive. The market initially ...